ABSTRACT Ninety-two patients with histologically confirmed bronchogenic carcinoma treated by surgical resection of the tumour were subsequently given immunotherapy with BCG (Glaxo). The patients were randomly allocated into three groups. Twenty-nine patients received multipuncture BCG (50 to 
results have been observed using BCG immunotherapy in acute lymphoblastic leukaemia5 and malignant melanoma6 7 although subsequent studies have given somewhat conflicting results.8 9 The theoretical basis of non-specific immunotherapy of lung cancer has been reviewed by Israel in 197310 and in subsequent years several trials of non-specific BCG immunotherapy in bronchogenic carcinoma have been reported and comprehensively reviewed by Hersh The constructed life tables for the 90 patients are illustrated in the figure. Although the median survival time for the intradermally treated group was 39 months compared to 24 months for both control and multipuncture groups, this was not statistically significant (p > 0 05). Similarly, the differences in the overall five-year survival figures of 41 % in the multipuncture treated group, 31 % in the intradermal treated group, and 37 % in the control group, were not statistically significant (p > 0 05).
The overall five-year survival in all 90 patients was 37 %, favourable prognostic features being squamous carcinoma (45 % five-year survival) as opposed to undifferentiated carcinoma (27%); and lobectomy (45 %) rather than pneumonectomy (28 %). When 
Discussion
This study has failed to demonstrate a significant 
